XM does not provide services to residents of the United States of America.
G
G

Gilead


News

U.S. Microstrategy, Snowflake, Target

U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target Nov 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Microstrategy, Snowflake and Target, on Thursday. HIGHLIGHTS * Dycom Industries Inc DY.N : D.A. Davidson raises target price to $220 from $210 * Microstrategy Inc MSTR.O : BTIG raises target price to $570 from $290 * Snowflake Inc SNOW.N : Piper Sandler raises target price to $185 from $165 * Target Corp TGT.
B
G
G
G
N
B
B
C
J
L

U.S. Airbnb, Post Holdings, Syndax Pharmaceuticals

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals Nov 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, Post Holdings and Syndax Pharmaceuticals, on Monday. HIGHLIGHTS * Airbnb Inc ABNB.O : D.A. Davidson raises PT to $131 from $125 * Korro Bio Inc KRRO.O : Jonestrading initiates coverage with buy rating; PT $130 * Post Holdings Inc POST.N : JP Morgan raises target price to $135 from $125 *
A
A
B
E
G
H
S
D
D
E
E
A
C
C
D
I

Gilead’S Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy And Long-Term Safety Profile In Management Of Primary Biliary Cholangitis

BRIEF-Gilead’S Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy And Long-Term Safety Profile In Management Of Primary Biliary Cholangitis Nov 15 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD’S LIVDELZI (SELADELPAR) DEMONSTRATED A SUSTAINED EFFICACY AND LONG-TERM SAFETY PROFILE IN MANAGEMENT OF PRIMARY BILIARY CHOLANGITIS GILEAD SCIENCE
G

Gilead Files For Four-Part Senior Notes Offering Size Not Disclosed - SEC Filing

BRIEF-Gilead Files For Four-Part Senior Notes Offering Size Not Disclosed - SEC Filing Nov 13 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD FILES FOR FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: [ID:n0001104659-24-117332] Further company coverage: GILD.O
G

US FDA declines full approval for Intercept's liver disease drug

CORRECTED-UPDATE 2-US FDA declines full approval for Intercept's liver disease drug Corrects expert's title to "associate professor" from "assistant professor" in paragraph 8 of Nov 12 story By Bhanvi Satija and Puyaan Singh Nov 12 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market.
G

Nasdaq top and bottom performing stocks at about 02:45 p.m. EST

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST Nasdaq 100 .NDX Top Performers Percent Change Super Micro Computer Inc SMCI.OQ +12.2% Warner Bros Discovery Inc WBD.OQ +10.9% Take-Two Interactive Software Inc TTWO.OQ +7.3% Trade Desk Inc TTD.OQ +5.3% Gilead Sciences Inc GILD.OQ +5.0% Bottom Performers Percent Change MercadoLibre Inc MELI.OQ -16.2% GlobalFoundries Inc GFS.OQ -4.3% Charter Communications Inc CHTR.OQ -3.7% CSX Corp CSX.OQ -3.2% Moderna Inc MRNA.OQ -3.0% The Na
C
C
G
M
T
U
T

U.S. STOCKS BorgWarner, Digital Realty, Take-Two

BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes added to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
M
N
D
T
U
U
B
L
V
A
B
C
M

U.S. STOCKS Ralph Lauren, CoreCivic, WK Kellogg

BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes held on to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
K
M
D
U
U
B
M
V
A
C
M

Gilead up after third-quarter results beat, forecast raise

BUZZ-Gilead up after third-quarter results beat, forecast raise Updates ** Drugmaker Gilead's GILD.O shares up 5 .7 % at $9 6.73; highest since April 2016 ** Company's Q3 results beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its forecast for FY earnings ** Q3 adj EPS of $2.02 and Q3 rev. of $7.5 bln beat analysts' ests., a ccording to data compiled by LSEG ** Com pany expects annual adj.
G

U.S. STOCKS Guardant Health, AppLovin, Sarepta

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq were set to open higher in the run-up to an interest-rate decision from the Federal Reserve on Thursday, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
U
U
B
V
A
C
M

Gilead up after Q3 results beat, forecast raise

BUZZ-Gilead up after Q3 results beat, forecast raise ** Drugmaker Gilead's GILD.O shares up 1.8% to $93.35 premarket ** Co's Q3 results beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its forecast for FY earnings ** Q3 adj EPS of $2.02 and Q3 rev of $7.5 bln beats analysts' ests, as per data compiled by LSEG ** Co expects annual adj EPS of $4.25 to $4.45, up from $3.60 to $3.90 earlier ** Raises FY product sales forecast to $27.8 bln to $28.1 bln fr
G

Street View: Investors eye Gilead's year-end filing for HIV drug lenacapavir

BUZZ-Street View: Investors eye Gilead's year-end filing for HIV drug lenacapavir ** Gilead Sciences GILD.O reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings ** Gilead plans to file for U.S. regulatory approval of le
G
J

U.S. BXP, Hubspot, Qualcomm

U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm Nov 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BXP, Hubspot and Qualcomm, on Thursday. HIGHLIGHTS * Aspen Technology Inc AZPN.O : Berenberg cuts to hold from buy * BXP Inc BXP.N : Scotiabank cuts to sector perform from sector outperform * Clearwater Analytics Holdings Inc CWAN.N : JP Morgan raises to overweight from neutral * Hubspot Inc HUBS.N : JP Morgan raises ta
A
C
G
D
L
A
A
C
I

Gilead Sciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Gilead Sciences Inc reports results for the quarter ended in September 30 - Earnings Summary Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.02​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $2.29. The mean expectation of twenty three analysts for the quarter was for earnings of $1.55 per share.
G

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook

UPDATE 1-Gilead 3rd-quarter results beat Wall Street estimates, raises outlook Adds CEO comment, paragraph 5, share price paragraph 6, analyst comment, paragraph 11 By Deena Beasley Nov 6 (Reuters) - Gilead Sciences GILD.O reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings.
G

US drugmakers muted after Trump's election victory

BUZZ-US drugmakers muted after Trump's election victory Updates ** U.S. drugmakers' shares trading up between 0.5% and 1% after Donald Trump elected as U.S. president ** Gilead GILD.O gains 1.4%, while Abbvie ABBV.N , Amgen AMGN.O Merck MRK.N , Bristol Myers BMY.N and J&J JNJ.N rise marginally ** Leerink analysts said they view Trump's win as mixed for large-cap biopharma since it creates potential uncertainty regarding U.S.
A
G
P

US drugmakers rise as Trump wins second US presidential term

BUZZ-US drugmakers rise as Trump wins second US presidential term ** Shares of some U.S. drugmakers rise between 1% and 3% premarket as Donald Trump wins second term at the White House ** Eli Lilly LLY.N shares gain 2.8%, Abbvie ABBV.N up about 2%, Amgen AMGN.O shares rise 1.5%, and Merck MRK.N up 1.3% ** Gilead GILD.O gains 1.2%, while Pfizer PFE.N and Bristol Myers BMY.N inch up about 1% in premarket trading ** BMO Capital had said ahead of elections that a Trump victory would be "net positive
A
G
P

Resounding Trump win sees dollar soar

MORNING BID AMERICAS-Resounding Trump win sees dollar soar A look at the day ahead in U.S. and global markets from Mike Dolan Donald Trump's surprisingly comprehensive victory in the U.S. Presidential election has electrified the U.S. dollar - possibly to his own chagrin - and the U.S. currency .DXY is eyeing its biggest one-day gain in two years.
E
G
M
Q
T
U
J
U
U
U
U
C
H
P
S
B

Kite To Highlight Industry-Leading Car T-Cell Therapy Portfolio At Ash 2024

BRIEF-Kite To Highlight Industry-Leading Car T-Cell Therapy Portfolio At Ash 2024 Nov 5 (Reuters) - Gilead Sciences Inc GILD.O : KITE TO HIGHLIGHT INDUSTRY-LEADING CAR T-CELL THERAPY PORTFOLIO AT ASH 2024, INCLUDING POSITIVE SURVIVAL OUTCOMES IN BOTH CLINICAL TRIALS AND THE REAL-WORLD Source text: ID:nBw2bRycWa Further company coverage: GILD.O ( Re
G

U.S. Amazon, Chevron, Mastercard

U.S. RESEARCH ROUNDUP-Amazon, Chevron, Mastercard Nov 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, Chevron and Mastercard, on Monday. HIGHLIGHTS * Amazon AMZN.O : Raymond James raises target price to $230 from $205 * Chevron Corp CVX.N : Raymond James raises target price to $175 from $170 * Mastercard MA.N : Macquarie raises target price to $565 from $505 * Vertex Inc VERX.O : Jefferies raises to buy fro
A
A
A
B
C
C
D
E
G
M
S
A
T
W
B
C
R
T



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.